A Phase I Study on Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of LP-118 in Patients With Advanced Malignancies
Latest Information Update: 13 Oct 2022
At a glance
- Drugs LP-118 (Primary)
- Indications B-cell lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Guangzhou Lupeng Pharmaceutical
- 08 Oct 2022 Planned number of patients changed from 76 to 96.
- 15 Sep 2021 Status changed from not yet recruiting to recruiting.
- 01 Sep 2021 New trial record